Posted in | News | Nanomedicine | Nanobusiness

Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries

Sigma-Aldrich, a leading life science company and member of The RNAi Consortium (TRC), proudly welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program. The RNAi Partnership Program provides new members with access to cutting-edge products in Sigma-Aldrich's functional genomics portfolio, including shRNA libraries developed by TRC targeting more than 15,000 human genes and 15,000 mouse genes.

"We are excited to become a member of the RNAi Partnership Program and we look forward to productive collaborations with our colleagues at Sigma- Aldrich," said Dr. Hakim Djaballah, Director of the High Throughput Screening Core Facility. "Many of our researchers are interested in targeted gene knockdown on an individual or gene-focused basis, as well as a genome-wide scale for which we are fully equipped. Access to Sigma-Aldrich's MISSION shRNA libraries will greatly enhance our current gene scanning capabilities and will enable us to discover and validate cancer-causing genes and pathways which will hopefully lead to novel approaches to therapeutic intervention for cancer patients."

Through the RNAi Partnership Program, Sigma-Aldrich aims to establish collaborations with select academic institutions. The company advances functional genomics research by aiding academic researchers with early exposure to emerging new techniques, a broad portfolio of intellectual property, and special partnership pricing on Sigma-Aldrich's extensive RNAi product lines. Existing members of the RNAi Partnership Program include The Cleveland Clinic, The Harvard Stem Cell Institute, Washington University of St. Louis, Princeton University, The Wistar Institute, and Rutgers University. These members enjoy unique access to cutting-edge RNAi tools for the study of basic gene function and the underlying causes of disease.

"Sigma-Aldrich is committed to expanding our collaborative relationships with prestigious institutions like the Memorial-Sloan Kettering Cancer Center," said Tim Fleming, Sigma-Aldrich's Director of Global Commercial Marketing for Life Sciences. "We look forward to the success of the Memorial Sloan-Kettering researchers utilizing our leading MISSION library, and will continue to look for innovative ways to accelerate our partners' success."

Sigma-Aldrich has recently made major commitments to the rapidly developing area of RNAi. This began with the establishment of research collaborations with the RNAi Consortium, followed by licensing agreements with MIT to make and sell the shRNA libraries developed by TRC and, subsequently, the introduction of Sigma-Aldrich's MISSION TRC shRNA libraries. Additional agreements with Alnylam, Benitec and Oxford BioMedica provide Sigma-Aldrich with a major intellectual property portfolio in RNAi.

For more information about The RNAi Consortium and participating members, please visit http://www.broad.mit.edu/rnai/trc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sigma Aldrich. (2019, February 15). Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries. AZoNano. Retrieved on March 01, 2024 from https://www.azonano.com/news.aspx?newsID=8137.

  • MLA

    Sigma Aldrich. "Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries". AZoNano. 01 March 2024. <https://www.azonano.com/news.aspx?newsID=8137>.

  • Chicago

    Sigma Aldrich. "Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries". AZoNano. https://www.azonano.com/news.aspx?newsID=8137. (accessed March 01, 2024).

  • Harvard

    Sigma Aldrich. 2019. Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries. AZoNano, viewed 01 March 2024, https://www.azonano.com/news.aspx?newsID=8137.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.